0001104659-23-075015.txt : 20230627
0001104659-23-075015.hdr.sgml : 20230627
20230627081215
ACCESSION NUMBER: 0001104659-23-075015
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230622
FILED AS OF DATE: 20230627
DATE AS OF CHANGE: 20230627
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brenner Martin
CENTRAL INDEX KEY: 0001770235
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35023
FILM NUMBER: 231044014
MAIL ADDRESS:
STREET 1: C/O PFENEX INC.
STREET 2: 10790 ROSELLE STREET
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iBio, Inc.
CENTRAL INDEX KEY: 0001420720
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262797813
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 600 MADISON AVENUE, SUITE 1601
CITY: NEW YORK
STATE: NY
ZIP: 10022-1737
BUSINESS PHONE: 302 355-0650
MAIL ADDRESS:
STREET 1: 600 MADISON AVENUE, SUITE 1601
CITY: NEW YORK
STATE: NY
ZIP: 10022-1737
FORMER COMPANY:
FORMER CONFORMED NAME: iBioPharma, Inc.
DATE OF NAME CHANGE: 20080806
FORMER COMPANY:
FORMER CONFORMED NAME: InB:Biotechnologies, Inc.
DATE OF NAME CHANGE: 20071210
4
1
tm2319771-1_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-06-22
0
0001420720
iBio, Inc.
IBIO
0001770235
Brenner Martin
C/O IBIO, INC.
8800 HSC PARKWAY
BRYAN
TX
77807
0
1
0
0
See Remarks
0
Common Stock
2023-06-22
4
D
0
75833
0
D
177578
D
Common Stock
2023-06-26
4
A
0
75833
0
A
253411
D
Consists of 75,833 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 75,833 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan") that expired prior to vesting.
Consists of 75,833 shares of the Company's common stock, represented by 75,833 RSUs granted under the Company's 2020 Plan. Each RSU represents a contingent right to receive one share of Common Stock. The 75,833 RSUs vest pro rata over a seven-month period, such vesting to terminate if Dr. Brenner is no longer the Company's Chief Executive Officer
Chief Executive Officer and Chief Scientific Officer
/s/ Martin Brenner
2023-06-27